Drug intelligence / Profile preview

epstein-barr virus vaccine

Development stage: Unknown
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics

Overview

The Epstein-Barr virus vaccine is an investigational vaccine candidate developed through a collaboration between OPKO Health and Merck. It is currently in a Phase 1 clinical trial to evaluate its safety and tolerability in healthy adult individuals. Merck will determine the subsequent development steps, including Phase 2 studies, based on the analysis of the Phase 1 results.

Other names: EBV vaccine

Beyond the preview

Go deeper on epstein-barr virus vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epstein-barr virus vaccine.

Explore the full profile